Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
language:"Undetermined"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=language%3A%22Undetermined%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=10
/vufind/Search/Results?filter%5B%5D=language%3A%22Undetermined%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=10
Search /vufind/Search2/Results?filter%5B%5D=language%3A%22Undetermined%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=10
PubPharm (1.244)
91
Relapsing Forms of multiple sclerosis (RMS) study of Bruton's Tyrosine Kinase (BTK) inhibitor Tolebrutinib (SAR442168) (GEMINI 1) : A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis - GEMINI 1
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
92
Vemurafenib (vem), cobimetinib (cobi) & atezolizumab (atezo) triplet combination in advanced melanoma : A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OFATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUSCOBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
93
Vemurafenib (vem), cobimetinib (cobi) & atezolizumab (atezo) triplet combination in advanced melanoma : A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION-POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
94
Vemurafenib (vem), cobimetinib (cobi) & atezolizumab (atezo) triplet combination in advanced melanoma : A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OFATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUSCOBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
95
Nonrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES) : A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES) - HERCULES
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
96
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's TyrosineKinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) : A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis - GEMINI 2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
97
A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TOEVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135)MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUSDARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTSWITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVERECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDINGLENALIDOMIDE AND A PROTEASOME INHIBITOR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
98
A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
99
Master Protocol for Avelumab Continuation Study : AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER SPONSORED AVELUMAB CLINICAL STUDIES
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
100
A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
[1]
« Vorheriger
5
6
7
8
9
10
11
12
13
14
15
Nächster »
[125]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Sprache: Unbestimmt
Medienart
1.244
Aufsätze
1.244
E-Artikel
1.244
E-Ressourcen
Zeitschriftentitel
1.244
WHO International Clinical Trials Registry Plat...
Thema
1.244
610
1.244
Recruitment Status: Authorised-recruitment may ...
1.244
Study Type: Interventional
334
Phase: Phase 3
156
Phase: Phase 2
120
Phase: Phase 4
36
Medical Condition: Relapsing Multiple Sclerosis...
34
Phase: Phase 1
28
Medical Condition: Primary Progressive Multiple...
26
Medical Condition: Non-relapsing Secondary Prog...
24
Medical Condition: Muscle Invasive Bladder Canc...
22
Medical Condition: Myelofibrosis MedDRA version...
16
Medical Condition: MULTIPLE MYELOMA MedDRA vers...
14
Medical Condition: Unresectable locally advance...
10
Medical Condition: HIV Infection;Therapeutic ar...
10
Medical Condition: Rheumatoid Arthritis MedDRA ...
8
Medical Condition: ;Therapeutic area: Diseases ...
8
Medical Condition: Solid Tumors MedDRA version:...
6
Medical Condition: ;Therapeutic area: Analytica...
6
Medical Condition: Asthma;Therapeutic area: Dis...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
434
2020-
810
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
Unbestimmt
Haven't found what you're looking for?
Wird geladen...